Shopping Cart
Remove All
Your shopping cart is currently empty
Ebronucimab
😃Good
Catalog No. T80608Cas No. 2304800-90-4
Alias AK102, AK 102
Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).
Ebronucimab
Ebronucimab
😃Good
Catalog No. T80608Alias AK102, AK 102Cas No. 2304800-90-4
Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $232 | - | In Stock | |
| 5 mg | $578 | - | In Stock | |
| 10 mg | $828 | - | In Stock | |
| 25 mg | $1,260 | - | In Stock | |
| 50 mg | $1,680 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:>95.0% (SDS-PAGE); 95.65% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH). |
| In vivo | In a multi-center randomized controlled trial conducted among Chinese patients with hypercholesterolemia, Ebronucimab, administered at 450 mg every 4 weeks or 150 mg every 2 weeks, significantly reduced serum LDL-C levels over 12 weeks (by approximately 59.13% and 60.43%, respectively), and showed high LDL-C goal achievement rates across different cardiovascular risk categories[1]. |
| Synonyms | AK102, AK 102 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PCSK9 |
| Molecular Weight | 144.76 kDa |
| Cas No. | 2304800-90-4 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ebronucimab | purchase Ebronucimab | Ebronucimab cost | order Ebronucimab | Ebronucimab in vivo | Ebronucimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.